6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
An open-label, randomized three-arm Phase II trial to explore the efficacy of BIBW 2992 as a
single agent versus lapatinib versus trastuzumab in patients with HER2-positive
treatment-naïve Stage IIIa locally advanced breast cancer. Additional information will be
obtained on the safety profile and pharmacokinetics of BIBW 2992.